MedCity Influencers

What if the individual mandate is overturned? (Best of MedCitizens)

Every week, MedCity News highlights the best of its MedCitizens: syndication partners and MedCity News readers who discuss life science current events on MedCityNews.com. Now here’s the best of what YOU had to say.

Every week, MedCity News highlights the best of its MedCitizens: syndication partners and MedCity News readers who discuss life science current events on MedCityNews.com.

Now here’s the best of what YOU had to say:

U.S. healthcare reform and the individual mandate: a prediction. “With the recent court decision, it seems reasonably likely we will end up in a situation where the individual mandate is overturned but the rest of the law is upheld. Observers have some thoughts on what would happen”…

FDA tells ‘fallen angel’ medical devices to submit PMAs or be taken off market. “‘All companies that previously had a 510(k) cleared would need to come in with a PMA within 90 days post August 23, 2011 if they are interested in continuing to market their device,’ FDA spokesperson Erica Jefferson told MassDevice. Products affected include certain ventricular bypass devices, pacemaker repair and replacement products and a type of female condom.”

Cleveland’s MetroHealth will thrive (not die) amid healthcare reform.Mark Twain’s quip that ‘news of my death was an exaggeration’ sums up my reaction to the article on MetroHealth: ‘Healthcare reform’s impact: Farewell to public hospitals like MetroHealth.’ The speculation that it’s all over for MetroHealth is wrong for three reasons.”

A fine line: Physician inventors, medical devices and device promotion. “Even if a doctor is convinced of the merits of a new device, compensation for promotion puts a cloud over the physician’s motives. Those of us in the field have all attended a scientific conference and witnessed a physician champion espousing the benefits of a product that we suspected were dubious. There is a fine line between a physician favorably presenting data at a conference and promotion of that medical device. The medical device industry has blurred that line with physician podium presentations that have become glorified PR releases.”

Boston Scientific takes a beating amid stock market chaos. BSX shares dipped below $6 per share for the first time in almost a year this week, going for $5.91 on Wednesday.

This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.

Topics